COVID-19 and HIV co-infection

COVID-19 Microchapters
Home
Long COVID
Frequently Asked Outpatient Questions
Frequently Asked Inpatient Questions
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating COVID-19 from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Vaccines
Secondary Prevention
Future or Investigational Therapies Ongoing Clinical Trials
Case Studies
Case #1
COVID-19 and HIV co-infection On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of COVID-19 and HIV co-infection All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on COVID-19 and HIV co-infection
CDC on COVID-19 and HIV co-infection
COVID-19 and HIV co-infection in the news
Blogs on COVID-19 and HIV co-infection
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for COVID-19 and HIV co-infection

Main article: COVID-19

For COVID-19 frequently asked inpatient questions, click here

For COVID-19 frequently asked outpatient questions, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Harmeet Kharoud M.D.[2]

Synonyms and keywords:

Overview

• An observational prospective study found out that the incidence of HIV-infected individuals to be affected by SARS-CoV-2 was similar to the general population.
• Specific antiretroviral therapy did not affect COVID-19 severity.
• Immunosuppression(low CD4 cell counts) was associated with COVID-19 severity.
• Patients with HIV infection often have other comorbidities(lung disease, cardiovascular disease) therefore, increasing the risk for severe-COVID-19 disease.

Epidemiology and Demographics

Risk

• At present people with HIV who are at greatest risk of Severe COVID-19 infection are people -
  • who have lowCD4 cell count.
  • not on antiretroviral therapy.

Presentation

• There hasn't been any observable difference in clinical presentation among people with HIV infection as compared to the general population.
• Common symptoms for COVID-19 are
  • Fever or chills
  • Cough
  • Shortness of Breath or difficulty breathing
  • Fatigue
  • Muscle or Body aches
  • Headache
  • New loss of taste or smell
  • Sore Throat
  • Congestion or runny nose
  • Nausea or vomiting
  • Diarrhea

Recommendations for Patients with HIV

• Maintain the supply for antiretroviral therapy for a minimum of 30 days.
• Virtual visit and telemedicine should be considered for non-urgent care and non-adherence counseling
• People with suppressed HIV viral load and in stable health, should postpone their routine medical care and laboratory visits to the extent possible.
• If they develop symptoms of COVID-19 like fever, cough, shortness of breath, etc they should seek medical advice.
• They should make sure their vaccination status is updated.